death from semaglutide Nurse's linked to weight-loss drug Mounjaro approved on NHS Kidney and Survival Benefits of

Telehealth Platforms Many telehealth services now offer Ozempic consultations and prescriptions

2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)

Semaglutide ameliorated pressure overload-induced cardiac hypertrophy by improving mitophagy to suppress the activation of NLRP3 inflammasome We next investigated the reason why improved mitophagy by semaglutide could ameliorate pressure overload-induced cardiac hypertrophy

STEP trials